Reversing Mitochondrial Dysfunction in Optineurin E50K Glaucoma: A Metabolic Approach to Neuroprotection

Reversing Mitochondrial Dysfunction in Optineurin E50K Glaucoma: A Metabolic Approach to Neuroprotection | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Reversing Mitochondrial Dysfunction in Optineurin E50K Glaucoma: A Metabolic Approach to Neuroprotection Bledi Petriti, Shobana Subramanian, Pete Williams, Kai-Yin Chau, and 8 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8380062/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted You are reading this latest preprint version Abstract Mutations in optineurin (OPTN) are linked to neurodegenerative diseases such as normal tension glaucoma (NTG) and amyotrophic lateral sclerosis. The E50K-OPTN mutation is the most common genetic cause of NTG, where it disrupts mitophagy and leads to the accumulation of dysfunctional mitochondria. To understand how cellular metabolism is altered in these persistent mitochondria, and whether any pathological state can be reversed, we investigated NTG-patient-derived fibroblasts carrying the E50K-OPTN mutation. We identified a form of mitochondrial leak metabolism driven by elevated levels of the ATP synthase c-subunit leak channel (ACLC). These cells exhibit reversed F1FO ATP synthase activity, increased mitochondrial proton leak, and fragmented mitochondria, resulting in inefficient oxidative phosphorylation and a shift toward aerobic glycolysis and high protein synthesis rate. The ratio of ATP synthase c-subunit to β-subunit was markedly elevated, suggesting open ACLC pores. Treatment with dexpramipexole normalized ATP synthase function and cellular metabolism, promoted ATP synthesis rather than hydrolysis and reduced protein synthesis rates. Dexpramipexole reduced p62 levels in E50K fibroblasts, consistent with a reduced mitophagic burden from decreased accumulation of damaged mitochondrial cargo. These findings identify ACLC-mediated leak as a central driver of metabolic dysfunction in E50K-OPTN glaucoma and suggest ACLC closure as a viable therapeutic strategy. Biological sciences/Cell biology/Mechanisms of disease Biological sciences/Cell biology/Autophagy/Mitophagy Full Text Additional Declarations There is NO Competing Interest. Cite Share Download PDF Status: Under Review Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8380062","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":562440740,"identity":"94ba9fc0-2429-442a-b953-19a270fce4ee","order_by":0,"name":"Bledi Petriti","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAElEQVRIiWNgGAWjYBACA3YGBokEMJOxgSGhgoGBD8TmwaeFGaqFh4GxsSHhDAMDG1FaoIoYGxjbiNBizsx88MYDhjty9tKH2x88nHdYno29gfHB2zbcWiyb2ZItEhieGfPwJTY2JG47bNjGc4DZcC4eLQaHecyAfjmc2MPDCNbC2CaRwCbNi1cL/zeQlnqIljmH7dvkH7D/xq+Fhw2kJYEHrKXhcGKbBAMbMz4tQL8YWyQYPDPsOcPYOCPhWHpyG09is+Scc7i1mLM3P7z5o+KOPHsP+4OPP2qsbfvZDx/88KYMtxao8w7AWM0M4GRABIBrqSNG9SgYBaNgFIwwAABMZk9nXUhGDgAAAABJRU5ErkJggg==","orcid":"","institution":"Yale School of Medicine","correspondingAuthor":true,"prefix":"","firstName":"Bledi","middleName":"","lastName":"Petriti","suffix":""},{"id":562440741,"identity":"7ac586ae-5380-407a-b499-9ed1a41f89d7","order_by":1,"name":"Shobana Subramanian","email":"","orcid":"","institution":"Yale School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Shobana","middleName":"","lastName":"Subramanian","suffix":""},{"id":562440742,"identity":"bcccac17-e26e-4fae-a948-af6feb8fafde","order_by":2,"name":"Pete Williams","email":"","orcid":"https://orcid.org/0000-0001-6194-8397","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Pete","middleName":"","lastName":"Williams","suffix":""},{"id":562440743,"identity":"dd091ded-ffd2-4f4e-92a2-3f75442500d3","order_by":3,"name":"Kai-Yin Chau","email":"","orcid":"","institution":"UCL Institute of Neurology","correspondingAuthor":false,"prefix":"","firstName":"Kai-Yin","middleName":"","lastName":"Chau","suffix":""},{"id":562440744,"identity":"8469e532-a216-4be8-8c08-e0c48897b177","order_by":4,"name":"Pawel Licznerski","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Pawel","middleName":"","lastName":"Licznerski","suffix":""},{"id":562440745,"identity":"2a53e29c-8a64-4d2d-bcc0-c4b90f4eaf9b","order_by":5,"name":"Gerassimos Lascaratos","email":"","orcid":"https://orcid.org/0000-0001-5936-1431","institution":"King's College Hospital NHS Foundation Trust","correspondingAuthor":false,"prefix":"","firstName":"Gerassimos","middleName":"","lastName":"Lascaratos","suffix":""},{"id":562440746,"identity":"2087dc08-81dd-4de4-ab15-45d3959779ca","order_by":6,"name":"Soledad Aguilar-Munoa","email":"","orcid":"","institution":"King's College Hospital NHS Foundation Trust","correspondingAuthor":false,"prefix":"","firstName":"Soledad","middleName":"","lastName":"Aguilar-Munoa","suffix":""},{"id":562440747,"identity":"cd8c64ee-3599-40f7-87af-8be8979905eb","order_by":7,"name":"Deborah Kamal","email":"","orcid":"","institution":"NIHR Biomedical Research Centre, Moorfields Eye Hospital","correspondingAuthor":false,"prefix":"","firstName":"Deborah","middleName":"","lastName":"Kamal","suffix":""},{"id":562440748,"identity":"da041647-742f-4025-8dce-9343a875598e","order_by":8,"name":"Haesoo Bae","email":"","orcid":"","institution":"Imperial College London","correspondingAuthor":false,"prefix":"","firstName":"Haesoo","middleName":"","lastName":"Bae","suffix":""},{"id":562440749,"identity":"db47a35f-8189-4d77-b8f6-3332a283f1b2","order_by":9,"name":"Kambiz Alavian","email":"","orcid":"","institution":"Imperial College","correspondingAuthor":false,"prefix":"","firstName":"Kambiz","middleName":"","lastName":"Alavian","suffix":""},{"id":562440750,"identity":"8629baf1-fca8-4f9b-87d1-18354bb923ec","order_by":10,"name":"David Garway-Heath","email":"","orcid":"https://orcid.org/0000-0003-2907-6992","institution":"Moorfields Eye Hospital and University College London","correspondingAuthor":false,"prefix":"","firstName":"David","middleName":"","lastName":"Garway-Heath","suffix":""},{"id":562440751,"identity":"07fab06d-f4ff-4634-8443-3dd4c266a552","order_by":11,"name":"Elizabeth Jonas","email":"","orcid":"https://orcid.org/0000-0002-1624-5999","institution":"Yale School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Elizabeth","middleName":"","lastName":"Jonas","suffix":""}],"badges":[],"createdAt":"2025-12-16 23:00:51","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8380062/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8380062/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":103029386,"identity":"bfaddb3d-ff65-4f7b-a896-343dc3600ea1","added_by":"auto","created_at":"2026-02-19 21:39:05","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":9544697,"visible":true,"origin":"","legend":"","description":"","filename":"E50KPaper16.12.2025.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8380062/v1_covered_84c696f0-6c9f-4f6b-a94f-017217cc0b7c.pdf"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"Reversing Mitochondrial Dysfunction in Optineurin E50K Glaucoma: A Metabolic Approach to Neuroprotection","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"nature-portfolio","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"","title":"Nature Portfolio","twitterHandle":"","acdcEnabled":false,"dfaEnabled":false,"editorialSystem":"ejp","reportingPortfolio":"","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-8380062/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8380062/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"Mutations in optineurin (OPTN) are linked to neurodegenerative diseases such as normal tension glaucoma (NTG) and amyotrophic lateral sclerosis. The E50K-OPTN mutation is the most common genetic cause of NTG, where it disrupts mitophagy and leads to the accumulation of dysfunctional mitochondria. To understand how cellular metabolism is altered in these persistent mitochondria, and whether any pathological state can be reversed, we investigated NTG-patient-derived fibroblasts carrying the E50K-OPTN mutation. We identified a form of mitochondrial leak metabolism driven by elevated levels of the ATP synthase c-subunit leak channel (ACLC). These cells exhibit reversed F1FO ATP synthase activity, increased mitochondrial proton leak, and fragmented mitochondria, resulting in inefficient oxidative phosphorylation and a shift toward aerobic glycolysis and high protein synthesis rate. The ratio of ATP synthase c-subunit to β-subunit was markedly elevated, suggesting open ACLC pores. Treatment with dexpramipexole normalized ATP synthase function and cellular metabolism, promoted ATP synthesis rather than hydrolysis and reduced protein synthesis rates. Dexpramipexole reduced p62 levels in E50K fibroblasts, consistent with a reduced mitophagic burden from decreased accumulation of damaged mitochondrial cargo. These findings identify ACLC-mediated leak as a central driver of metabolic dysfunction in E50K-OPTN glaucoma and suggest ACLC closure as a viable therapeutic strategy.","manuscriptTitle":"Reversing Mitochondrial Dysfunction in Optineurin E50K Glaucoma: A Metabolic Approach to Neuroprotection","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-02-19 21:38:21","doi":"10.21203/rs.3.rs-8380062/v1","editorialEvents":[],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"nature-communications","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"NCOMMS","sideBox":"Learn more about [Nature Communications](http://www.nature.com/ncomms/)","snPcode":"","submissionUrl":"https://mts-ncomms.nature.com/","title":"Nature Communications","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature Communications","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"a33d9814-e61a-4f4d-892a-d87c522245c1","owner":[],"postedDate":"February 19th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":59895278,"name":"Biological sciences/Cell biology/Mechanisms of disease"},{"id":59895279,"name":"Biological sciences/Cell biology/Autophagy/Mitophagy"}],"tags":[],"updatedAt":"2026-02-19T21:38:24+00:00","versionOfRecord":[],"versionCreatedAt":"2026-02-19 21:38:21","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8380062","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8380062","identity":"rs-8380062","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}